Recent
FDA suspends Intellia’s gene-editing therapy trials for ATTR due to repeated severe liver complications, raising safety and industry concerns.
October 31, 2025
Source:
Intellia Therapeutics
Background and FDA Action
The U.S. Food and Drug Administration (FDA) issued a clinical hold on Intellia Therapeutics’ gene-editing therapy trials for transthyretin amyloidosis (ATTR) following a second severe liver complication in a patient (BioPharma Dive). The patient suffered a 'grade 4' spike in liver enzymes and bilirubin, leading to hospitalization. This follows an earlier incident in May 2025, where a similar spike was reported but did not require hospital admission (STAT News).
Nature of the Events
Both incidents involved potentially life-threatening liver toxicity appearing weeks after gene-editing treatment.
The recurrence of grade 4 events in separate patients signals a possible pattern of risk in the therapy’s safety profile.
Keep up with the story. Subscribe to the PR+ free daily newsletter
Source:
Getty Images
Company Response and Medical Context
Intellia Therapeutics has paused patient dosing and increased liver enzyme monitoring while it investigates the cause of toxicity. Initial analysis suggests the risk may stem from the targeted gene rather than the lipid nanoparticle delivery system (Clinical Trials Arena).
Current Treatments for ATTR
ATTR already has approved oral and injectable therapies with strong safety records, including tafamidis and patisiran, that are widely available (STAT News).
Intellia’s CRISPR therapy aimed to offer a potential one-time cure via permanent gene editing, but safety issues now overshadow this potential advantage.
Regulatory and Industry Impact
The FDA hold is a major setback for Intellia as confidence in in vivo CRISPR therapies is being reassessed across the industry. Investors and scientists are closely monitoring the situation (Global Genes).
Read More
Source:
Bloomberg
Industry Reactions and Safety Debate
Public and Expert Concerns
Recurring liver complications have sparked debate among medical experts and investors about the future of gene-editing for rare diseases.
The risk-benefit equation for gene-editing is under scrutiny, given safer alternatives for ATTR.
Broader Implications
Concerns may extend to other Intellia programs, though initial analysis points risk to the ATTR gene target specifically (BioPharma Dive).
This case is seen as a critical crossroads for in vivo CRISPR safety, possibly impacting regulatory paths for future therapies.
For visual context, related coverage includes images of Intellia labs, CRISPR mechanisms, and liver enzyme test results (Global Genes).
What are the potential long-term effects of liver complications from gene-editing therapies?
Long-term effects can include chronic liver damage, risk of liver failure, and the need for ongoing medical monitoring or intervention.
How do lipid nanoparticles contribute to liver enzyme elevations?
What alternative treatments are available for transthyretin amyloidosis?
How does Intellia plan to address the safety concerns with their CRISPR therapy?
What are the implications of this FDA hold on Intellia's future clinical trials?
Share this news:
